Cmblu Energy Ag

Biocompatibles UK Limited

Cmblu Projekt Ag

Cellmed Ag

Peter Geigle

Wolfgang Straub

Jan Hartwig

Evgeny Larionov

Christine Wallrapp

Eric Thoenes

Frank Thürmer

Alexander Moeller

Nastaran Krawczyk

Roland Reiner

Herma Glöckner

Alexander Möller

Eduard Baal

Steffen Kerker

The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.

Aminated lignin-derived compounds and uses thereof

The present invention relates to novel combinations of redox active compounds for use as redox flow battery electrolytes. The invention further provides kits comprising these combinations, redox flow batteries, and method using the combinations, kits and redox flow batteries of the invention.

Redox flow battery electrolytes

The invention relates to novel methods for processing lignocellulosic material. More specifically, the invention proves an integrated approach for processing cellulose to obtain paper and pulp and valorizing lignin to obtain value-added chemicals and products.

Methods for processing lignocellulosic material

Sulfonated lignin-derived compounds and uses thereof

Redox-active compounds and uses thereof

The present invention relates to a method for producing one or more low molecular weight aromatic lignin-derived compounds. The method preferably comprises providing lignocellulosic material, subjecting the lignocellulosic material to a pulping process, separating pulp to provide a substantially pulp-free process stream comprising a modified lignin-derived component, isolating the modified lignin-derived component, subjecting the isolated modified lignin-derived component to a decomposition step comprising oxidative cracking (cracking and oxidizing) or reducing under the influence of a catalyst or electro-oxidation, and subjecting the resulting products to an isolation step, to provide a low molecular weight aromatic lignin-derived compound. Said compound may be further modified, e.g. by annulation. The inventive method preferably comprises further oxidizing said compound to a redox active compound. Additionally, the present invention relates to compounds obtainable by the inventive method and to an assembly for carrying out the inventive method. Furthermore, the present invention refers to a method for providing an existing pulp and/or paper manufacturing plant with said assembly.

Method for producing low molecular weight aromatic lignin-derived compounds

Sulfonated aromatic compounds

The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

GLP-1 Fusion Peptides

The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders and diseases or conditions associated thereto, neurodegenerative disorders and diseases or conditions associated thereto, or for the treatment of disorders and diseases or conditions associated to apoptosis.

Spherical microcapsules comprising GLP-1 peptides, their production and use

The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II)C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

GLP-1 fusion peptides, their production and use

The invention relates to the use of implantable microcapsules, or microparticles or gels produced from alginates that are crosslinked with bivalent or multivalent cations or that are uncrosslinked, for the treatment of skin defects such as e.g. wrinkles, for the treatment of gastro-oesophageal reflux, urinary incontinence and vesico-ureteral reflux.

Growing community of inventors

Alzenau, Germany

Peter Geigle